Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Neuronetics, Inc.NASDAQ: STIM
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital dips below year-ago levels
Q1 FY2026 change in working capital of $1.83M (cash outflow) fell 73.3% year over year, behind the +270.0% change in trailing-twelve-month change in working capital.
Context
- Change in working capital amounted to 4.4% of revenue in FY2025, down 4.7 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -73.3% toward the trailing-twelve-month pace of +270.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 6.58M USD
- Year-over-year change
- +196.6%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.58M | +196.6% |
| FY2024 | 2024-12-31 | (6.81M) | +51.7% |
| FY2023 | 2023-12-31 | (14.1M) | -175.7% |
| FY2022 | 2022-12-31 | (5.12M) | +22.9% |
| FY2021 | 2021-12-31 | (6.64M) | — |
Change in Working Capital vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +270.0% is the highest of 9, against a peer median of -52.4%.
- Change in working capital amounts to 7.6% of revenue for STIM, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.6M USD | +270.0% | — | 7.6% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $8.07M USD | -47.6% | — | 1.9% |
| LTM Mar 2026 | $7.29M USD | -27.6% | -23.0% | 25.2% | |
| LTM Mar 2026 | $5.73M USD | -418.7% | -32.3% | 30.4% | |
| LTM Mar 2026 | $5.7M USD | -57.2% | -62.8% | 16.5% | |
| LTM Mar 2026 | $4.85M USD | -42.7% | -54.1% | 4.3% | |
| LTM Mar 2026 | $4.58M USD | -40.8% | -33.2% | 5.9% | |
| LTM Mar 2026 | $2.39M USD | — | — | 2.1% | |
| LTM Mar 2026 | €1.55M EUR | -127.9% | +296.7% | 9.5% | |
| LTM Mar 2026 | $1.48M USD | -243.2% | +70.7% | 239.8% | |
| Peer median (excluding STIM) | — | -52.4% | -32.3% | 9.5% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.